Gradientech at ESCMID Global 2024
The diagnostics company Gradientech announces the presentation of new performance data from clinical, real-world evaluations with its QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST) at ESCMID Global 2024 in Barcelona, Spain, April 27th-30th.
ESCMID Global, organised by ESCMID - European Society of Clinical Microbiology and Infectious Diseases, is one of the most comprehensive and influential congresses in infectious diseases and microbiology, bringing together over 16,000 professionals from all over the world. Gradientech has two abstracts at the event, including one oral presentation, which will highlight clinical data from QuickMIC® studies in both low and high resistance settings, together with new results on early resistance prediction by the QuickMIC system using machine learning algorithms. Four additional abstracts by external clinical sites will present QuickMIC performance data.
“This year I am extra proud as we have an an all-time high in number of QuickMIC studies being presented. Gradientech is additionally releasing our new Ebook “Stop treating all patients equally” during the congress. All together this gives us a golden opportunity to highlight and talk about how an ultra-rapid system with precise MIC values can advance AST to the next level. The Gradientech team looks forward to meet and discuss around this with leading experts in the field during ESCMID Global,” says Sara Thorslund, CEO and co-founder at Gradientech.
Discover QuickMIC® at ESCMID Global 2024
April 27th-30th
Fira Gran Via, Barcelona
Gradientech Booth D28, Exhibition Hall
QuickMIC studies presented
|
Abstract title |
Presentation details |
|
Machine-learning assisted early flagging of extended-spectrum beta-lactamase harbouring resistant bacterial strains in a phenotypic rapid AST system, Reibenspies L et al. |
Oral session, O1009 |
|
Ability of two rapid phenotypic AST methods to detect carbapenem resistance in Gram-negative bacteria directly from positive blood cultures, Degel-Broßmann N et al. |
Poster session, P1606 Date: 29/04/2024 Time: 12:00 – 13:30 |
|
Performance of a Novel Microfluidic Rapid AST Assay for Gram-Negative Bloodstream Infections in Low and High Resistance Settings, Malmberg C et al. |
Poster session, P1602
|
|
Evaluation of a novel system for rapid antimicrobial susceptibility testing of Gram-negative pathogens from positive blood cultures, Morecchiato F et al. |
Poster session, P1636 Time: 12:00 – 13:30 CET |
|
Evaluation of a new system for rapid antimicrobial susceptibility of Gram-negative bacteria directly from positive blood cultures, Tartaglione L et al. |
Poster session, P1637 Time: 12:00 – 13:30 CET |
|
Evaluation of the QuickMIC Rapid Antibiotic Susceptibility Testing Assay with carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates, Réka M et.al |
Poster session, P1609 |
The QuickMIC system's ultra-rapid and precise AST results enable sepsis patients to receive specific personalised guidance of the right antibiotic and the right dose in record time. The modular design offers affordable scaling possibilities, making QuickMIC attractive to both small and large hospital laboratories. QuickMIC and its Gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.
